In Re Urohealth Systems, Inc.

252 F.3d 504, 2001 U.S. App. LEXIS 12150, 2001 WL 635958
CourtCourt of Appeals for the First Circuit
DecidedJune 12, 2001
Docket00-2458
StatusPublished
Cited by32 cases

This text of 252 F.3d 504 (In Re Urohealth Systems, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Urohealth Systems, Inc., 252 F.3d 504, 2001 U.S. App. LEXIS 12150, 2001 WL 635958 (1st Cir. 2001).

Opinion

BOWNES, Senior Circuit Judge.

Defendant-petitioner Urohealth Systems, Inc. petitioned for an extraordinary *505 writ to review the district court’s stay-order in this product liability action. Uro-health contends that the district court flouted the instructions in our earlier order in this case, Doe v. Urohealth Systems, Inc., 216 F.3d 157 (1st Cir.2000), and abused its discretion in ordering the stay. We construe the extraordinary writ as an appeal, vacate the stay order, and remand for further proceedings.

I. BACKGROUND

On August 6, 1997, plaintiff John Doe sued Urohealth in the United States District Court for the District of Rhode Island. He asserted claims of strict liability, negligence, and breach of warranty based on the alleged malfunction of a penile prosthesis implanted on February 23, 1996. 1

Discovery proceeded for sixteen months. During that time, the district court chastised Doe for various abuses, including designating in interrogatory answers multiple experts that he had never in fact retained; not prosecuting his case diligently; and propounding voluminous and inappropriate discovery requests at the end of the discovery period. At the initial close of discovery, Doe had not yet retained an expert.

Urohealth first moved for summary judgment on June 23, 1998. The district court extended the pretrial deadlines, and Doe retained Edward Reese, Ph.D., as an expert. In response, Urohealth supplemented its motion for summary judgment, contending that Dr. Reese was unqualified and that his opinions lacked foundation. The district court assigned that motion to a magistrate judge, who ordered Uro-health to file a separate Daubert motion to strike Dr. Reese. Urohealth did so on January 11,1999.

On January 26, 1999, Doe sued Uro-health and Urohealth’s wholly-owned subsidiary, Dacomed Corporation, in the Rhode Island Superior Court, asserting the same product liability claims as in the instant case. In the state court action, Doe also sued the physician who implanted the prosthesis, Dr. Alan Podis, and the treating hospital, Miriam Hospital.

On February 15, 1999, Doe moved to dismiss the federal court action without prejudice under Fed.R.Civ.P. 41(a)(2). Urohealth opposed the motion. In deciding the motion, the district court correctly considered “the defendant’s effort and expense of preparation for trial, excessive delay and lack of diligence on the part of the plaintiff in prosecuting the action, insufficient explanation for the need to take a dismissal, and the fact that a motion for summary judgment has been filed by the defendant.” Urohealth, 216 F.3d at 160 (quoting Pace v. S. Express Co., 409 F.2d 331, 334 (7th Cir.1969)). As we summarized in our earlier opinion:

The district court then indicated that, even though the Pace factors favored Urohealth, it did not believe that Uro-health would “truly suffer legal prejudice” if it dismissed the federal lawsuit without prejudice because Urohealth still would have to litigate these claims on behalf of Dacomed in the state suit. Urohealth argued that if the district court denied Doe’s Rule 41(a)(2) motion and granted Urohealth summary judgment, the judgment would have preclusive effect for both Urohealth and Dacomed; thus, Urohealth could avoid relitigating the case in state court. The district court disagreed, reasoning that even if summary judgment would preclude relitigation for *506 Urohealth in the state ease, Daeomed, which “is a separate entity, albeit wholly owned by Urohealth,” would not be protected by res judicata because it was not a defendant in the federal case.

Id. at 161.

Urohealth appealed the district court’s order of dismissal without prejudice. This court reversed the order on the ground that “the district court’s main stated reason for dismissing without prejudice was based on a legal error.” Id. at 162-63. Specifically, we held that the district court erred in assuming that Daeomed would not be entitled to assert a res judicata defense in state court if Urohealth had won summary judgment in the federal action. We stated:

An evaluation of the res judicata effects normally would not be part of the Rule 41(a)(2) analysis, but this ease is unusual because of the relationship of the two entities. To the extent the district court permissibly considered the potential prejudice stemming from Urohealth’s having to litigate on behalf of Daeomed in the state case, we find an abuse of discretion because the court erred in finding no privity between the companies.

Id. at 161. We remanded the case to the district court, leaving open the narrow possibility that the district court could, for other reasons, dismiss the case without ruling on Urohealth’s motion for summary judgment. Id. at 163.

On remand, the case was assigned to a different district court judge, who ordered the parties to file new memoranda supporting and opposing the motion to dismiss. On November 8, 2000, the district court issued an order to stay the federal matter until the resolution of parallel state court proceedings. It stated:

I have at times stayed the federal action to await the outcome of the state case because the state outcome could make this litigation moot, and since the state case is the more comprehensive case, I think that’s the most judicially economic result in this case. So I’m not going to rule on the motion to dismiss without prejudice or with prejudice. I’m going to stay this case until the state court litigation is completed, and then I will determine whether there’s anything left to do, or decide, in this matter.

On November 24, 2000, Urohealth petitioned this court for an extraordinary writ under Fed. R.App. P. 21(c). On December 28, 2000, we issued an order conditionally treating the extraordinary writ as a notice of appeal. We stated:

it appears that an extraordinary writ does not lie because the challenged order is appealable.... Nonetheless, there is precedent for treating a petition for an extraordinary writ as a notice of appeal ... and we exercise our discretion to do so under the peculiar circumstances of this case.

(citations omitted). We deferred the final disposition of the question of our jurisdiction to the merits panel.

II. DISCUSSION

The first question before us is whether we have jurisdiction over this matter, given that Urohealth petitioned for an extraordinary writ rather than noticing a direct appeal of the stay order.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re US
Federal Circuit, 2026
Jennifer T. v. Lindsay P.
298 Neb. 800 (Nebraska Supreme Court, 2018)
In re: JPMorgan Chase Bank, NA v.
799 F.3d 36 (First Circuit, 2015)
John Cottrell v. Michael Duke
737 F.3d 1238 (Eighth Circuit, 2013)
Lennon v. Dacomed Corp.
901 A.2d 582 (Supreme Court of Rhode Island, 2006)
Shulas v. Estabrook
895 A.2d 1234 (New Jersey Superior Court App Division, 2006)
Fremaint v. Ford Motor Co.
258 F. Supp. 2d 24 (D. Puerto Rico, 2003)
Lennon v. Dacomed Corporation, 99-0387 (2003)
Superior Court of Rhode Island, 2003

Cite This Page — Counsel Stack

Bluebook (online)
252 F.3d 504, 2001 U.S. App. LEXIS 12150, 2001 WL 635958, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-urohealth-systems-inc-ca1-2001.